查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1984180

新抗原癌症疫苗市場：依新抗原類型、治療標靶、疫苗平台、給藥途徑和最終用戶分類－2026-2032年全球市場預測

Neoantigen Cancer Vaccine Market by Neoantigen Type, Therapeutic Target, Vaccine Platform, Administration Route, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，新抗原癌症疫苗市場價值將達到 175.1 億美元，到 2026 年將成長至 196.5 億美元，到 2032 年將達到 415.8 億美元，複合年成長率為 13.15%。

主要市場統計數據
基準年 2025 175.1億美元
預計年份：2026年 196.5億美元
預測年份 2032 415.8億美元
複合年成長率 (%) 13.15%

對新抗原癌症疫苗進行簡明介紹，整合科學創新、臨床進展和相關人員的策略考量。

新抗原癌症疫苗代表了腫瘤學領域的模式轉移，它利用腫瘤特異性肽段特徵誘導針對惡性腫瘤的適應性免疫。這些治療方法的核心在於利用腫瘤特異性突變或復發性腫瘤相關改變產生的獨特或通用新抗原（抗原決定簇）精確誘導T細胞反應。定序、生物資訊學和合成生物學的進步縮短了從發現到生產的周期，使得從腫瘤切片檢查到候選疫苗的快速轉化成為可能。這種技術融合已將新抗原疫苗從概念性的可能性轉變為涵蓋學術機構、生物技術公司和臨床聯盟的強大轉化流程。

對技術、臨床、製造和監管領域的變革性變化進行分析概述，重新定義新抗原疫苗向下一代創新發展的前景。

新抗原疫苗領域正經歷一場變革，這場變革由四個相互關聯的因素驅動：技術成熟度、聯合治療的臨床檢驗、不斷發展的供應鏈以及不斷變化的監管預期。技術成熟度包括腫瘤定序處理能力的提升、表位預測演算法的改進以及能夠提高抗原表達保真度的新一代RNA和DNA遞送平台。這些進步消除了候選疫苗篩選的瓶頸，並使得設計更具免疫抗原性的構建體成為可能。因此，研發人員正在探索諸如環狀DNA支架和新一代RNA化學等創新平台，以加速疫苗的最佳化，並提高其穩定性和免疫啟動能力。

對計劃於 2025 年進行的美國關稅調整將如何影響整個新抗原疫苗生態系統的供應鏈選擇、製造地和籌資策略進行現實評估。

美國正在實施或計劃於2025年實施的關稅政策對新抗原疫苗研發企業的商業決策產生了重大影響。尤其值得注意的是，該領域依賴全球分散的試劑、合成寡核苷酸、脂質奈米顆粒、特殊耗材和生物製程設備等供應基地。提高進口試劑和組件的關稅可能會增加原料的取得成本，這可能會擠壓早期研發企業（尤其是那些採購量較小的企業）的利潤空間。為此，許多機構正在調整籌資策略，優先選擇國內或區域供應商，重新與供應商談判契約，並加快對替代來源的認證，以確保關鍵原料供應的持續性。

透過整合新抗原類型、治療標靶、疫苗平台、給藥途徑和最終用戶等因素，進行全面的細分洞察，從而指導策略優先排序。

市場區隔為評估新抗原疫苗的臨床應用、技術選擇和商業化路徑提供了一個實用的架構。根據新抗原的類型，市場被分類為「個人化新抗原」和「通用新抗原」共用類。 「個人化新抗原」透過免疫逃脫突變和體細胞突變進行更深入的研究，而「共用新抗原」則著重於親和性和胜肽和常見腫瘤突變進行評估。這種細分有助於明確治療範圍。個人化策略優先考慮根據個別突變譜客製化的抗原庫，而共用策略則針對複發性突變，以實現更廣泛的患者應用並提供現成產品。

美洲、歐洲、中東和非洲以及亞太地區新抗原疫苗開發的關鍵區域趨勢和操作考慮因素。

區域趨勢對新抗原疫苗計畫的研發強度、監管環境、生產策略和市場進入有顯著影響。在美洲，豐富的創新環境、廣泛的臨床試驗網路和雄厚的私人資本支持技術的快速實用化；然而，複雜的支付方環境和臨床實驗中心的推出等後勤物流可能會影響專案進度。美國尤其如此，它仍然是平台創新和首次人體試驗的中心，其遍布北美的網路促進了多中心試驗和公私合營。

對新抗原疫苗商業化過程中的平台領導者、合作模式和智慧財產權趨勢進行策略競爭格局分析。

新抗原疫苗領域呈現出多元化的格局，既有專注於個人化治療的先鋒生物技術公司，也有將新抗原平台整合到更廣泛的腫瘤免疫產品組合中的領先腫瘤公司。主要企業致力於提昇平台的穩健性（抗原預測的準確性、生產速度和抗原呈現的廣度），而策略夥伴則負責擴大生產規模、分銷管道以及後期臨床開發。學術研究機構仍然是轉化創新的重要來源，它們進行早期臨床試驗，以檢驗抗原選擇方法和聯合治療。

為產業領導者提供切實可行的建議，以協調平台創新、監管合作和供應鏈韌性，從而確保新抗原疫苗計畫的成功。

產業領導者應採取多管齊下的策略，將科學差異化、營運韌性和市場准入計畫結合。首先，應優先投資於能夠縮短從腫瘤定序到疫苗上市時間的平台，這些平台應整合先進的預測演算法、自動化生產流程和可靠的品管檢測方法。同時，應建立靈活的生產夥伴關係和區域供應鏈，以降低關稅風險並確保關鍵原料的持續供應。

一種透明且可重複的調查方法，它結合了與專家的初步訪談、嚴格的二次分析和結構化的技術評估框架。

本研究整合了對臨床研究人員、監管專家、生產負責人和商業負責人的訪談，以及對同行評審文獻、臨床試驗註冊資料和公開監管指南的二次分析。資料收集過程中注重可重複性。具體而言，訪談通訊協定經過標準化，以了解專案設計選擇、營運挑戰和策略重點，並將定性回答與已記錄的案例研究和監管申報文件進行交叉核對，以確保準確性。

具有前瞻性的結論，融合了科學進步、運作挑戰和協作方法，以促進新抗原疫苗的廣泛應用。

新抗原癌症疫苗正處於一個轉折點，科學的成熟與營運創新相融合，開啟了新的治療可能性。抗原預測技術的改進、多樣化的遞送平台以及策略性臨床聯合治療的整合，正在建立一條從藥物發現到患者應用的可行路徑。同時，供應鏈脆弱性、監管協調以及可擴展生產的需求等實際挑戰，需要謹慎的策略應對，才能將免疫學潛力轉化為廣泛可及的療法。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：新抗原癌症疫苗市場（以新抗原類型分類）

  • 個人化新抗原
    • 免疫逃脫突變
    • 體細胞突變
  • 共用的新抗原
    • 親和性肽
    • 通用腫瘤突變

第9章：按治療標靶分類的新抗原癌症疫苗市場

  • 免疫查核點抑制
    • CTLA-4抑制劑
    • PD-1抑制劑
  • 腫瘤新抗原
    • 突變新抗原
    • 非突變新抗原

第10章：以疫苗平台分類的新抗原癌症疫苗市場

  • 細胞疫苗
    • 樹突細胞疫苗
    • T細胞疫苗
  • DNA疫苗
    • 環狀DNA平台
    • 質體DNA疫苗
  • 基於胜肽的疫苗
    • 長鏈胜肽
    • 合成胜肽
  • 基於RNA的疫苗
    • 藥效疫苗
    • 下一代RNA平台

第11章 新抗原癌症疫苗市場（依給藥途徑分類）

  • 皮內注射
  • 靜脈
  • 口服
  • 皮下

第12章：新抗原癌症疫苗市場：依最終用戶分類

  • 癌症治療中心
  • 醫院
  • 研究機構

第13章：新抗原癌症疫苗市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 新抗原癌症疫苗市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：新抗原癌症疫苗市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國新抗原癌症疫苗市場

第17章：中國新抗原癌症疫苗市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Agenus Inc.
  • AstraZeneca PLC
  • Avidea Technologies
  • Ayala Pharmaceuticals, Inc.
  • BioLineRx Ltd.
  • BioNTech SE
  • BioVaxys Technology Corp.
  • Brightpath Biotherapeutics Co., Ltd.
  • CureVac NV
  • Elicio Therapeutics Inc
  • F. Hoffmann-La Roche Ltd.
  • Geneos Therapeutics, Inc. by Inovio Pharmaceuticals, Inc.
  • Genocea Biosciences Inc
  • GenScript Biotech Corporation
  • Gilead Sciences, Inc.
  • Gritstone bio, Inc.
  • Immunomic Therapeutics, Inc.
  • ISA Pharmaceuticals BV
  • Medigene AG
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Neophore Limited
  • Nouscom AG
  • Nykode Therapeutics ASA
  • OSE Immunotherapeutics
  • Takis Srl
Product Code: MRR-5C6F41F5AFED

The Neoantigen Cancer Vaccine Market was valued at USD 17.51 billion in 2025 and is projected to grow to USD 19.65 billion in 2026, with a CAGR of 13.15%, reaching USD 41.58 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 17.51 billion
Estimated Year [2026] USD 19.65 billion
Forecast Year [2032] USD 41.58 billion
CAGR (%) 13.15%

A concise introduction to neoantigen cancer vaccines that synthesizes scientific innovation, clinical momentum, and strategic considerations for stakeholders

Neoantigen cancer vaccines represent a paradigm shift in oncology, harnessing tumor-specific peptide signatures to mobilize adaptive immunity against malignancies. At their core, these interventions exploit unique or shared neoantigens-antigenic determinants arising from tumor-specific mutations or recurrent tumor-associated changes-to direct T cell responses with precision. Advances in sequencing, bioinformatics, and synthetic biology have compressed the discovery-to-manufacture timeline, enabling more rapid translation from tumor biopsy to vaccine candidate. This technical convergence has moved neoantigen vaccines from conceptual promise to a robust translational pipeline across academic centers, biotechnology companies, and clinical consortia.

Clinically, neoantigen strategies are being evaluated across monotherapy settings and in combination with established modalities such as immune checkpoint inhibitors and adoptive cell therapies. The evidence base emphasizes immunogenicity, safety, and the capacity to broaden antitumor T cell repertoires. Operationally, the space demands interdisciplinary coordination-genomics, antigen prediction, GMP manufacturing, and clinical operations-creating both opportunities and complexity for developers and their partners. Consequently, strategic clarity around segmentation, regional dynamics, supply chain resilience, and commercialization pathways has become essential for stakeholders aiming to convert scientific advances into durable clinical and commercial outcomes.

An analytical synthesis of the transformative technological, clinical, manufacturing, and regulatory shifts redefining the neoantigen vaccine landscape for the next wave of innovation

The neoantigen vaccine landscape is undergoing transformative shifts driven by four interlocking forces: technological maturation, clinical validation of combination approaches, supply chain evolution, and shifting regulatory expectations. Technological maturation spans improvements in tumor sequencing throughput, enhanced algorithms for epitope prediction, and next-generation RNA and DNA delivery platforms that increase antigen expression fidelity. These advances have reduced bottlenecks in candidate identification while enabling the design of more immunogenic constructs. As a result, developers are iterating faster and exploring innovative platforms such as circular DNA scaffolds and next-gen RNA chemistries to improve stability and immune priming.

Clinically, emerging data from studies that pair neoantigen vaccines with immune checkpoint blockade have catalyzed a move from purely experimental protocols to structured combinatorial strategies with clearer endpoints. This clinical momentum is accompanied by changes in manufacturing paradigms; decentralized and regionalized production models are being piloted to shorten turnaround times and address cold chain dependencies. Regulatory frameworks are also adapting, with agencies increasingly open to streamlined pathways for individualized biologics while emphasizing standardized potency assays and robust pharmacovigilance. Together, these shifts are redefining how programs are designed, financed, and brought to patients, emphasizing modular, scalable approaches and strategic partnerships across the ecosystem.

A pragmatic assessment of how United States tariff adjustments slated for 2025 are shaping supply chain choices, manufacturing footprints, and procurement strategies across the neoantigen vaccine ecosystem

Tariff policies implemented or anticipated by the United States for 2025 have had a material influence on the operational calculus of neoantigen vaccine developers, particularly because the sector relies on an internationally distributed supply base for reagents, synthetic oligonucleotides, lipid nanoparticles, specialized consumables, and bioprocess equipment. Increased duties on imported reagents and components raise the landed cost of inputs and can compress margins for early-stage developers who lack purchasing scale. In response, many organizations have adjusted procurement strategies to prioritize domestic or regional suppliers, renegotiated supplier contracts, and accelerated qualification of alternative sources to maintain continuity of critical raw materials.

Beyond unit cost implications, cumulative tariff effects have reinforced the strategic rationale for nearshoring and regional manufacturing. Developers and contract manufacturers are increasingly evaluating the trade-offs between capitalizing on lower-cost offshore production and accepting longer lead times and tariff exposure. At the same time, tariffs have prompted greater attention to supply chain transparency, inventory planning, and dual-sourcing to mitigate single-source risk. On the policy front, developers are engaging more actively with trade associations and regulators to clarify tariff classifications for biologics and associated materials, seeking exemptions or tariff relief when feasible. Collectively, these adjustments are shaping decision-making around facility investment, partnership selection, and program timelines without altering the fundamental scientific trajectories of neoantigen vaccine development.

Comprehensive segmentation insights that integrate neoantigen types, therapeutic targets, vaccine platforms, administration routes, and end users to guide strategic prioritization

Segmentation offers a pragmatic framework to evaluate clinical applications, technology choices, and commercialization pathways for neoantigen vaccines. Based on neoantigen type, the market is studied across Personalized Neoantigens and Shared Neoantigens; Personalized Neoantigens are further examined through immune escape mutations and somatic mutations, while Shared Neoantigens are assessed with attention to affinity peptides and common tumor mutations. This segmentation clarifies therapeutic scope: personalized approaches prioritize bespoke antigen repertoires tailored to an individual's mutational landscape, whereas shared strategies target recurrent alterations that enable broader patient applicability and potential off-the-shelf offerings.

Based on therapeutic target, the market is studied across Immune Checkpoint Blockade and Tumor Neoantigens; Immune Checkpoint Blockade is further examined across CTLA-4 inhibitors and PD-1 inhibitors, and Tumor Neoantigens are further parsed into mutated neoantigens and non-mutated neoantigens. This axis highlights the importance of combinatorial design and target selection in optimizing immune activation. Based on vaccine platform, the market is studied across Cell-Based Vaccines, DNA-Based Vaccines, Peptide-Based Vaccines, and RNA-Based Vaccines; Cell-Based Vaccines are further examined across dendritic cell vaccines and T-cell vaccines, DNA-Based Vaccines are further explored across circular DNA platforms and plasmid DNA vaccines, Peptide-Based Vaccines are further categorized into long peptides and synthetic peptides, and RNA-Based Vaccines are further evaluated across mRNA vaccines and next-generation RNA platforms. This platform segmentation illuminates trade-offs in manufacturing complexity, antigen expression durability, and dosing strategies. Based on administration route, the market is studied across intradermal, intravenous, oral, and subcutaneous delivery, an axis that affects immunogenicity, patient experience, and clinical logistics. Finally, based on end user, the market is studied across cancer treatment centers, hospitals, and research institutes, underscoring where clinical adoption, trial execution, and translational research investment are concentrated. Together, these segmentation lenses enable strategic prioritization of clinical indications, platform investments, and partner selection to maximize translational and commercial impact.

Key regional dynamics and operational considerations for neoantigen vaccine development across the Americas, Europe Middle East & Africa, and Asia-Pacific regions

Regional dynamics exert a strong influence on R&D intensity, regulatory timelines, manufacturing strategy, and commercial access for neoantigen vaccine programs. In the Americas, an innovation-rich environment with extensive clinical trial networks and significant private capital supports rapid technology translation, though program timelines can be affected by complex payer landscapes and site activation logistics. The United States in particular remains a center for platform innovation and first-in-human studies, while broader North American networks facilitate multi-center studies and public-private collaborations.

In Europe, Middle East & Africa, diverse regulatory jurisdictions and a strong foundation in academic translational research create opportunities for collaborative consortia and harmonized clinical evaluation through centralized regulatory mechanisms. Several countries within the region are advancing clinical infrastructure and adaptive trial frameworks conducive to personalized biologics. Asia-Pacific presents a heterogeneous landscape characterized by fast-growing biotech clusters, government-led incentives for biomanufacturing, and rapidly expanding clinical trial capacity. Emerging markets in the region are increasingly investing in local manufacturing capabilities and regulatory modernization, which can accelerate regional access but also necessitate tailored regulatory and commercialization strategies. Developers must therefore adopt a region-specific approach to partnerships, clinical site selection, and manufacturing footprint planning to align with differing regulatory expectations, reimbursement environments, and patient access pathways.

Strategic competitive landscape analysis highlighting platform leaders, partnership models, and intellectual property dynamics shaping neoantigen vaccine commercialization

The competitive landscape for neoantigen vaccines features a spectrum of organizations, from pioneering biotechs focusing on individualized approaches to larger oncology companies integrating neoantigen platforms into broader immuno-oncology portfolios. Leading developers concentrate on platform robustness-accuracy of antigen prediction, speed of manufacturing, and breadth of antigen presentation-while strategic collaborators provide scale in production, distribution, and late-stage clinical development. Academic centers remain crucial sources of translational innovation, hosting early trials that validate antigen selection methods and combination regimens.

Partnership models are evolving: strategic alliances with contract development and manufacturing organizations accelerate GMP translation; licensing deals with platform owners enable larger firms to access specialized antigen-prediction algorithms; and collaborative networks with clinical consortia expedite multicenter studies. Investment patterns prioritize platforms that can reduce time from sequence to product, support modular manufacturing, and de-risk regulatory pathways through standardized assay development. Intellectual property around epitope selection algorithms, delivery chemistry, and manufacturing processes is a differentiator, influencing strategic positioning and M&A interest as stakeholders seek to integrate vertical capabilities and shorten commercialization timelines.

Actionable recommendations for industry leaders to align platform innovation, regulatory engagement, and supply chain resilience for successful neoantigen vaccine programs

Industry leaders should adopt a multi-pronged strategy that aligns scientific differentiation with operational resilience and market access planning. First, prioritize platform investments that reduce turnaround time from tumor sequencing to vaccine release by integrating advanced prediction algorithms, automated manufacturing workflows, and robust quality control assays. Concurrently, establish flexible manufacturing partnerships and regional supply relationships to mitigate tariff exposures and ensure continuity of critical inputs.

Second, design clinical programs that emphasize strategic combinations with immune checkpoint inhibitors and standardized endpoints that resonate with regulators and payers. Early engagement with regulatory authorities to align on potency assays, safety monitoring frameworks, and evidence-generation plans will streamline later-stage development. Third, pursue modular commercialization strategies that balance personalized and shared neoantigen approaches; leverage shared neoantigen candidates to create scalable offerings while using personalized programs to address high-unmet-need indications. Finally, invest in cross-functional capabilities-data management, regulatory science, and health economics-to articulate value to payers, accelerate reimbursement discussions, and support sustainable adoption pathways.

A transparent and reproducible research methodology integrating primary expert interviews, rigorous secondary analysis, and structured technology assessment frameworks

This research synthesizes primary interviews with clinical investigators, regulatory experts, manufacturing leaders, and commercial strategists, alongside secondary analysis of peer-reviewed literature, clinical trial registries, and public regulatory guidance. Data collection emphasized reproducible methods: interview protocols were standardized to capture program design choices, operational challenges, and strategic priorities, and qualitative responses were triangulated with documented case studies and regulatory filings to ensure accuracy.

Analytical methods combined thematic analysis of qualitative inputs with technology assessment frameworks to evaluate platform readiness, manufacturability, and scalability. Risk assessments focused on supply chain dependencies, regulatory heterogeneity, and clinical development complexity. Comparative profiling of platforms and programs used consistent criteria-development stage, platform maturity, manufacturing complexity, and strategic partnerships-to support clear, comparable insights. Throughout, the methodology prioritized transparency and traceability so that conclusions can be validated against primary sources and updated as new data emerge.

A forward-looking conclusion that synthesizes scientific progress, operational imperatives, and collaborative pathways to advance neoantigen vaccine adoption

Neoantigen cancer vaccines are at an inflection point where scientific maturation and operational innovation are jointly unlocking new therapeutic possibilities. The convergence of improved antigen prediction, diversified delivery platforms, and strategic clinical combinations is creating viable pathways from discovery to patient administration. At the same time, practical challenges-supply chain exposures, regulatory harmonization, and the need for scalable manufacturing-require deliberate strategic responses to translate immunological promise into broadly accessible treatments.

Looking forward, success will favor organizations that combine scientific differentiation with operational discipline: those that can validate antigen selection empirically, demonstrate consistent manufacturing quality, and articulate economic value to payers. Collaborative ecosystems-linking developers, CDMOs, clinical networks, and regulators-will accelerate progress, while region-specific manufacturing and regulatory strategies will shape access. In sum, the field presents compelling opportunities for stakeholders who can integrate translational science with pragmatic execution to bring next-generation neoantigen vaccines into clinical practice.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Neoantigen Cancer Vaccine Market, by Neoantigen Type

  • 8.1. Personalized Neoantigens
    • 8.1.1. Immune Escape Mutations
    • 8.1.2. Somatic Mutations
  • 8.2. Shared Neoantigens
    • 8.2.1. Affinity Peptides
    • 8.2.2. Common Tumor Mutations

9. Neoantigen Cancer Vaccine Market, by Therapeutic Target

  • 9.1. Immune Checkpoint Blockade
    • 9.1.1. CTLA-4 Inhibitors
    • 9.1.2. PD-1 Inhibitors
  • 9.2. Tumor Neoantigens
    • 9.2.1. Mutated Neoantigens
    • 9.2.2. Non-Mutated Neoantigens

10. Neoantigen Cancer Vaccine Market, by Vaccine Platform

  • 10.1. Cell-Based Vaccines
    • 10.1.1. Dendritic Cell Vaccines
    • 10.1.2. T-Cell Vaccines
  • 10.2. DNA-Based Vaccines
    • 10.2.1. Circular DNA Platforms
    • 10.2.2. Plasmid DNA Vaccines
  • 10.3. Peptide-Based Vaccines
    • 10.3.1. Long Peptides
    • 10.3.2. Synthetic Peptides
  • 10.4. RNA-Based Vaccines
    • 10.4.1. mRNA Vaccines
    • 10.4.2. Next-Gen RNA Platforms

11. Neoantigen Cancer Vaccine Market, by Administration Route

  • 11.1. Intradermal
  • 11.2. Intravenous
  • 11.3. Oral
  • 11.4. Subcutaneous

12. Neoantigen Cancer Vaccine Market, by End User

  • 12.1. Cancer Treatment Centers
  • 12.2. Hospitals
  • 12.3. Research Institutes

13. Neoantigen Cancer Vaccine Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Neoantigen Cancer Vaccine Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Neoantigen Cancer Vaccine Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Neoantigen Cancer Vaccine Market

17. China Neoantigen Cancer Vaccine Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Agenus Inc.
  • 18.6. AstraZeneca PLC
  • 18.7. Avidea Technologies
  • 18.8. Ayala Pharmaceuticals, Inc.
  • 18.9. BioLineRx Ltd.
  • 18.10. BioNTech SE
  • 18.11. BioVaxys Technology Corp.
  • 18.12. Brightpath Biotherapeutics Co., Ltd.
  • 18.13. CureVac N.V.
  • 18.14. Elicio Therapeutics Inc
  • 18.15. F. Hoffmann-La Roche Ltd.
  • 18.16. Geneos Therapeutics, Inc. by Inovio Pharmaceuticals, Inc.
  • 18.17. Genocea Biosciences Inc
  • 18.18. GenScript Biotech Corporation
  • 18.19. Gilead Sciences, Inc.
  • 18.20. Gritstone bio, Inc.
  • 18.21. Immunomic Therapeutics, Inc.
  • 18.22. ISA Pharmaceuticals B.V.
  • 18.23. Medigene AG
  • 18.24. Merck & Co., Inc.
  • 18.25. Moderna, Inc.
  • 18.26. Neophore Limited
  • 18.27. Nouscom AG
  • 18.28. Nykode Therapeutics ASA
  • 18.29. OSE Immunotherapeutics
  • 18.30. Takis S.r.l.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NEOANTIGEN CANCER VACCINE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE ESCAPE MUTATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE ESCAPE MUTATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE ESCAPE MUTATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SOMATIC MUTATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SOMATIC MUTATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SOMATIC MUTATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY AFFINITY PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY AFFINITY PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY AFFINITY PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COMMON TUMOR MUTATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COMMON TUMOR MUTATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COMMON TUMOR MUTATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY MUTATED NEOANTIGENS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY MUTATED NEOANTIGENS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY MUTATED NEOANTIGENS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NON-MUTATED NEOANTIGENS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NON-MUTATED NEOANTIGENS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NON-MUTATED NEOANTIGENS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DENDRITIC CELL VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DENDRITIC CELL VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DENDRITIC CELL VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY T-CELL VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY T-CELL VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY T-CELL VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CIRCULAR DNA PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CIRCULAR DNA PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CIRCULAR DNA PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PLASMID DNA VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PLASMID DNA VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PLASMID DNA VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY LONG PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY LONG PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY LONG PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SYNTHETIC PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SYNTHETIC PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SYNTHETIC PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY MRNA VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY MRNA VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY MRNA VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEXT-GEN RNA PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEXT-GEN RNA PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEXT-GEN RNA PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY INTRADERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY INTRADERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY INTRADERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CANCER TREATMENT CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CANCER TREATMENT CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CANCER TREATMENT CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. GCC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 237. GCC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. GCC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 239. GCC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 240. GCC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2032 (USD MILLION)
  • TABLE 241. GCC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2032 (USD MILLION)
  • TABLE 242. GCC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 243. GCC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 244. GCC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 245. GCC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 246. GCC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 247. GCC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 248. GCC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 249. GCC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPEAN UNION NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPEAN UNION NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 267. BRICS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 268. BRICS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2032 (USD MILLION)
  • TABLE 269. BRICS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2032 (USD MILLION)
  • TABLE 270. BRICS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 271. BRICS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 272. BRICS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 274. BRICS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 275. BRICS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 277. BRICS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 278. G7 NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 279. G7 NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. G7 NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 281. G7 NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 282. G7 NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2032 (USD MILLION)
  • TABLE 283. G7 NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2032 (USD MILLION)
  • TABLE 284. G7 NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 285. G7 NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 286. G7 NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 287. G7 NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 288. G7 NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 289. G7 NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 290. G7 NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 291. G7 NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 292. NATO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 293. NATO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 294. NATO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 295. NATO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 296. NATO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2032 (USD MILLION)
  • TABLE 297. NATO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2032 (USD MILLION)
  • TABLE 298. NATO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 299. NATO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 300. NATO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 301. NATO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 302. NATO NEOANTIGEN CANCER